Trial Outcomes & Findings for Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains (NCT NCT02718157)

NCT ID: NCT02718157

Last Updated: 2021-05-03

Results Overview

To establish the performance characteristics of the GenePOC GBS System for its use in determining the presence of GBS in vaginal/rectal swab, after Lim Broth enrichment, specimens from antepartum pregnant women. Sensitivity and specificity will be established in comparison to the Reference Method. Sensitivity performance results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Reference Method only. Sensitivity is reported as a percentage (i.e. concondant positives / concordant positive + discordant positive (\[False Negative\]). Specificity performance results from the comparison of specimens being reported as negative by both method against the total number of specimen reported as negative on the Reference Method only. Specificity is reported as a percentage (i.e. concondant negatives / concordant negatives + discordant negatives (\[False Positive\]).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

771 participants

Primary outcome timeframe

At the time of the results with Reference Method is confirmed, up to 6 months

Results posted on

2021-05-03

Participant Flow

Participant milestones

Participant milestones
Measure
Accuracy Testing
Comparison between GenePOC PCR and Reference Method Comparison between GenePOC PCR and Reference Method: Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Overall Study
STARTED
771
Overall Study
COMPLETED
609
Overall Study
NOT COMPLETED
162

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Accuracy Testing
n=771 Participants
Comparison between GenePOC PCR and Reference Method Comparison between GenePOC PCR and Reference Method: Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Age, Categorical
<=18 years
0 Participants
n=771 Participants
Age, Categorical
Between 18 and 65 years
771 Participants
n=771 Participants
Age, Categorical
>=65 years
0 Participants
n=771 Participants
Sex: Female, Male
Female
771 Participants
n=771 Participants
Sex: Female, Male
Male
0 Participants
n=771 Participants
Region of Enrollment
Canada
238 participants
n=771 Participants
Region of Enrollment
United States
533 participants
n=771 Participants

PRIMARY outcome

Timeframe: At the time of the results with Reference Method is confirmed, up to 6 months

To establish the performance characteristics of the GenePOC GBS System for its use in determining the presence of GBS in vaginal/rectal swab, after Lim Broth enrichment, specimens from antepartum pregnant women. Sensitivity and specificity will be established in comparison to the Reference Method. Sensitivity performance results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Reference Method only. Sensitivity is reported as a percentage (i.e. concondant positives / concordant positive + discordant positive (\[False Negative\]). Specificity performance results from the comparison of specimens being reported as negative by both method against the total number of specimen reported as negative on the Reference Method only. Specificity is reported as a percentage (i.e. concondant negatives / concordant negatives + discordant negatives (\[False Positive\]).

Outcome measures

Outcome measures
Measure
Accuracy Testing
n=771 Participants
Comparison between GenePOC PCR and Reference Method Comparison between GenePOC PCR and Reference Method: Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Performance Characteristics
Sensitivity
95.9 percentage of specimens
Interval 91.7 to 98.0
Performance Characteristics
Specificity
95.5 percentage of specimens
Interval 93.5 to 96.9

SECONDARY outcome

Timeframe: At the time of the results with Reference Method is confirmed, up to 6 months

To estimate the Positive and Negative Predictive Values (PPV and NPV) of the GenePOC GBS System. PPV results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Investigational test only. PPV is reported as a percentage (i.e. concondant positives / concordant positive + discordant positive (\[False Positive\]). NPV results from the comparison of specimens being reported as negative by both method against the total number of specimen reported as negative on the Investigational test only. NPV is reported as a percentage (i.e. concondant negatives / concordant negatives + discordant negatives (\[False Negative\]).

Outcome measures

Outcome measures
Measure
Accuracy Testing
n=771 Participants
Comparison between GenePOC PCR and Reference Method Comparison between GenePOC PCR and Reference Method: Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Positive and Negative Predictive Values
PPV
85.8 percentage of specimens
Interval 80.1 to 90.0
Positive and Negative Predictive Values
NPV
98.8 percentage of specimens
Interval 97.5 to 99.4

SECONDARY outcome

Timeframe: At the time of the results with Reference Method is confirmed, up to 6 months

To estimate the rate of unresolved results for the GenePOC GBS System due to Sample Processing control failure (unresolved sample results).

Outcome measures

Outcome measures
Measure
Accuracy Testing
n=771 Participants
Comparison between GenePOC PCR and Reference Method Comparison between GenePOC PCR and Reference Method: Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Unresolved Sample Results
0.74 percentage of Unresolved
Interval 0.34 to 1.6

SECONDARY outcome

Timeframe: At the time of the results with Reference Method is confirmed, up to 6 months

To estimate the rate of indeterminate results for the GenePOC GBS Test due to an Instrument failure (indeterminate sample results).

Outcome measures

Outcome measures
Measure
Accuracy Testing
n=771 Participants
Comparison between GenePOC PCR and Reference Method Comparison between GenePOC PCR and Reference Method: Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Indeterminate Sample Results
1.48 percentage of Indeterminates
Interval 0.85 to 2.57

Adverse Events

Accuracy Testing

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr Keith Chiasson, PhD

GenePOC

Phone: 418-650-3535

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place